WASHINGTON, Sept. 20, 2018 /PRNewswire/ -- Vanda
Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that a
HETLIOZ® patent, number 10,071,977 ('977
patent), is now listed in the U.S. Food and Drug
Administration publication Approved Drug Products With
Therapeutic Equivalence Evaluations, commonly known as the Orange
Book. The '977 patent was issued by the United States Patent
and Trademark Office on September 11, 2018 and expires in
February 2035. Prior to this newly listed '977 patent, the
HETLIOZ® Orange Book listed patent with the latest
expiry date was set to expire in May 2034.
About Vanda
Vanda is a global biopharmaceutical company focused on the
development and commercialization of innovative therapies to
address high unmet medical needs and improve the lives of patients.
For more on Vanda Pharmaceuticals Inc., please
visit www.vandapharma.com.
Company Contact:
Jim Kelly
Executive Vice President and Chief Financial Officer
Vanda Pharmaceuticals Inc.
(202) 734-3428
jim.kelly@vandapharma.com
View original
content:http://www.prnewswire.com/news-releases/vanda-announces-listing-of-a-new-hetlioz-patent-in-the-fda-orange-book-300716505.html
SOURCE Vanda Pharmaceuticals Inc.